Comparative study shows dapagliflozin is more effective in reducing cardiotoxicity in rats, suggesting a potential treatment option.
DAPA is a promising new cardioprotective medication against DOX-related cardiotoxicity. Cardiotoxicity is better controlled with DAPA than Cr by suppressing oxidative stress, apoptosis, and upregulation of the antioxidant Nrf-2/HO-1/NQO1 genes.
No takes yet. Share an insight, caveat, or question.
Shaban et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: